Does the media prefer BBIO or LEGN?

In the previous week, Legend Biotech had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 15 mentions for Legend Biotech and 10 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.30 beat Legend Biotech's score of 0.34 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LEGN or ASND?

In the previous week, Legend Biotech had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 15 mentions for Legend Biotech and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.51 beat Legend Biotech's score of 0.34 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer LEGN or ELAN?

In the previous week, Legend Biotech had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 15 mentions for Legend Biotech and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.72 beat Legend Biotech's score of 0.34 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 15 mentions for Legend Biotech and 11 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.77 beat Legend Biotech's score of 0.34 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LEGN or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Legend Biotech. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 15 mentions for Legend Biotech. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Legend Biotech's score of 0.34 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Legend Biotech (LEGN) Competitors

$18.55 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$18.58 +0.03 (+0.17%)

As of 07/31/2026 07:55 PM Eastern

Compare

LEGN vs. BBIO, ASND, ELAN, AXSM, and ARWR

Should you buy Legend Biotech stock or one of its competitors? MarketBeat compares Legend Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Legend Biotech include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), and Arrowhead Pharmaceuticals (ARWR).

How does Legend Biotech compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

BridgeBio Pharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Legend Biotech has a net margin of -21.98% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Legend Biotech	-21.98%	-24.92%	-14.87%

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Legend Biotech had 5 more articles in the media than BridgeBio Pharma. MarketBeat recorded 15 mentions for Legend Biotech and 10 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 1.30 beat Legend Biotech's score of 0.34 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma currently has a consensus target price of $95.21, suggesting a potential upside of 18.88%. Legend Biotech has a consensus target price of $55.29, suggesting a potential upside of 198.04%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Legend Biotech has higher revenue and earnings than BridgeBio Pharma. Legend Biotech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$579.96M	27.00	-$724.93M	-$3.74	N/A
Legend Biotech	$1.03B	3.35	-$296.80M	-$0.68	N/A

Summary

BridgeBio Pharma beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Ascendis Pharma A/S?

Legend Biotech (NASDAQ:LEGN) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ascendis Pharma A/S has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.35	-$296.80M	-$0.68	N/A
Ascendis Pharma A/S	$814.57M	18.68	-$258M	$8.67	28.13

Ascendis Pharma A/S has a net margin of 57.87% compared to Legend Biotech's net margin of -21.98%. Ascendis Pharma A/S's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

In the previous week, Legend Biotech had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 15 mentions for Legend Biotech and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.51 beat Legend Biotech's score of 0.34 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Legend Biotech presently has a consensus price target of $55.29, suggesting a potential upside of 198.04%. Ascendis Pharma A/S has a consensus price target of $296.72, suggesting a potential upside of 21.65%. Given Legend Biotech's higher probable upside, equities research analysts clearly believe Legend Biotech is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Legend Biotech has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Legend Biotech on 13 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Elanco Animal Health?

Legend Biotech (NASDAQ:LEGN) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Elanco Animal Health has higher revenue and earnings than Legend Biotech. Elanco Animal Health is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.35	-$296.80M	-$0.68	N/A
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Legend Biotech currently has a consensus target price of $55.29, suggesting a potential upside of 198.04%. Elanco Animal Health has a consensus target price of $28.73, suggesting a potential upside of 8.72%. Given Legend Biotech's higher possible upside, research analysts plainly believe Legend Biotech is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Legend Biotech had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 15 mentions for Legend Biotech and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.72 beat Legend Biotech's score of 0.34 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Elanco Animal Health has a net margin of -4.95% compared to Legend Biotech's net margin of -21.98%. Elanco Animal Health's return on equity of 7.42% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Legend Biotech on 12 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Legend Biotech had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 15 mentions for Legend Biotech and 11 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.77 beat Legend Biotech's score of 0.34 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics presently has a consensus price target of $261.29, suggesting a potential upside of 19.86%. Legend Biotech has a consensus price target of $55.29, suggesting a potential upside of 198.04%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Axsome Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Axsome Therapeutics has higher earnings, but lower revenue than Legend Biotech. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A
Legend Biotech	$1.03B	3.35	-$296.80M	-$0.68	N/A

Legend Biotech has a net margin of -21.98% compared to Axsome Therapeutics' net margin of -26.59%. Legend Biotech's return on equity of -24.92% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

Axsome Therapeutics beats Legend Biotech on 9 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Arrowhead Pharmaceuticals?

Legend Biotech (NASDAQ:LEGN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.35	-$296.80M	-$0.68	N/A
Arrowhead Pharmaceuticals	$829.45M	14.38	-$1.63M	-$2.15	N/A

Legend Biotech currently has a consensus price target of $55.29, suggesting a potential upside of 198.04%. Arrowhead Pharmaceuticals has a consensus price target of $96.92, suggesting a potential upside of 14.49%. Given Legend Biotech's higher possible upside, equities research analysts plainly believe Legend Biotech is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Legend Biotech has a net margin of -21.98% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Legend Biotech's return on equity of -24.92% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Legend Biotech. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 15 mentions for Legend Biotech. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Legend Biotech's score of 0.34 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Summary

Legend Biotech beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.45B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-27.28	7.38	282.30	24.66
Price / Sales	3.35	1,201.52	564.98	76.51
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.42	16.78	10.92	6.07
Net Income	-$296.80M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-3.74%	-1.79%	-0.64%	-0.44%
1 Month Performance	-37.98%	-8.41%	-5.24%	-4.81%
1 Year Performance	-52.19%	48.37%	61.98%	18.61%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	3.0922 of 5 stars	$18.55 flat	$55.29 +198.0%	-52.2%	$3.45B	$1.03B	N/A	2,965
BBIO BridgeBio Pharma	3.3152 of 5 stars	$84.12 +0.1%	$95.21 +13.2%	+69.1%	$16.46B	$502.08M	N/A	400	Positive News Upcoming Earnings Gap Up
ASND Ascendis Pharma A/S	4.8256 of 5 stars	$253.42 -0.2%	$296.72 +17.1%	+39.8%	$15.83B	$814.57M	29.23	1,189	Positive News Upcoming Earnings
ELAN Elanco Animal Health	2.9495 of 5 stars	$25.48 +2.3%	$28.73 +12.7%	+91.5%	$12.44B	$4.72B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
AXSM Axsome Therapeutics	3.3115 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+111.6%	$12.40B	$638.50M	N/A	380	Upcoming Earnings Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. BBIO, ASND, ELAN, AXSM, and ARWR

How does Legend Biotech compare to BridgeBio Pharma?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Summary

How does Legend Biotech compare to Elanco Animal Health?

Summary

How does Legend Biotech compare to Axsome Therapeutics?

Summary

How does Legend Biotech compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. BBIO, ASND, ELAN, AXSM, and ARWR

How does Legend Biotech compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or LEGN?

Is BBIO or LEGN more profitable?

Do insiders and institutionals hold more shares of BBIO or LEGN?

Does the media prefer BBIO or LEGN?

Do analysts recommend BBIO or LEGN?

Which has higher valuation & earnings, BBIO or LEGN?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Do institutionals and insiders have more ownership in LEGN or ASND?

Which has higher earnings & valuation, LEGN or ASND?

Is LEGN or ASND more profitable?

Does the media prefer LEGN or ASND?

Do analysts rate LEGN or ASND?

Which has more volatility & risk, LEGN or ASND?

Summary

How does Legend Biotech compare to Elanco Animal Health?

Which has better earnings & valuation, LEGN or ELAN?

Do insiders and institutionals have more ownership in LEGN or ELAN?

Do analysts prefer LEGN or ELAN?

Does the media prefer LEGN or ELAN?

Which has more risk & volatility, LEGN or ELAN?

Is LEGN or ELAN more profitable?

Summary

How does Legend Biotech compare to Axsome Therapeutics?

Do insiders and institutionals have more ownership in AXSM or LEGN?

Does the media favor AXSM or LEGN?

Do analysts recommend AXSM or LEGN?

Which has more volatility & risk, AXSM or LEGN?

Which has better valuation and earnings, AXSM or LEGN?

Is AXSM or LEGN more profitable?

Summary

How does Legend Biotech compare to Arrowhead Pharmaceuticals?

Do institutionals and insiders have more ownership in LEGN or ARWR?

Which has preferable valuation and earnings, LEGN or ARWR?

Do analysts recommend LEGN or ARWR?

Is LEGN or ARWR more profitable?

Does the media prefer LEGN or ARWR?

Which has more risk & volatility, LEGN or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools